Cancer immunotherapy: Macs in the middle
- PMID: 33691132
- DOI: 10.1016/j.immuni.2021.02.012
Cancer immunotherapy: Macs in the middle
Abstract
Response to immune checkpoint blockade cancer immunotherapy is variable, but the mechanisms that underlie this variability remain unclear. In a recent issue of Nature Medicine, Yu et al. demonstrate that liver metastases limit immunotherapy efficacy by promoting macrophage-mediated elimination of tumor-specific CD8+ T cells. Liver-directed radiotherapy in preclinical models could partially overcome this effect.
Crown Copyright © 2021. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests S.T. receives research funding from Bristol-Myers Squibb and Iovance Biotherapeutics.
Comment on
-
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination.Nat Med. 2021 Jan;27(1):152-164. doi: 10.1038/s41591-020-1131-x. Epub 2021 Jan 4. Nat Med. 2021. PMID: 33398162 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials